Aclarion, Inc. SEC 10-Q Report

Aclarion, Inc., a company specializing in advanced medical imaging solutions, has released its Q3 2023 10-Q report. The report provides a comprehensive overview of the company's financial and operational performance, showcasing significant growth in revenue and strategic business developments. Below are the key highlights from the report. Financial Highlights Total Revenue: $18,942, driven by the growing volume of NOCISCAN® reports sold into the UK market following recent local coverage decisions.Gross Profit (Loss): $4,386, an improvement of $11,311 compared to the same period in 2024, primarily due to a reduced allocation of hosting fees to cost of revenue and a change in revenue mix that reduced partner fees.Loss from Operations: $(1,830,964), reflecting increased sales and marketing expenses due to expanded use of external consultants and initiation of the Clarity trial.Net Loss: $(1,706,294), with a decrease in interest expense and loss on exchange of debt compared to the previous year.Net Loss Per Share Allocable to Common Shareholders: $(2.93), reflecting the impact of increased operating expenses and reduced interest expenses. Business Highlights Geographical Performance: The company experienced a significant increase in revenue from the UK market, driven by the growing volume of NOCISCAN® reports following recent local coverage decisions. This trend is expected to continue as more insurance payors are brought on board.Sales Units: The company reported an increase in the number of NOCISCAN® reports sold, particularly in the UK market, which contributed to the overall revenue growth.Operational Efficiency: The company achieved a reduction in the cost of revenue due to a decreased allocation of hosting fees and a change in revenue mix that reduced partner fees.Research and Development: The company increased its research and development expenses, focusing on patent maintenance and regulatory compliance, which are expected to support future product development and market expansion.Sales and Marketing Expansion: There was a significant increase in sales and marketing expenses, primarily due to the initiation of the Clarity trial and expanded use of external consultants to support market development.Future Outlook: The company anticipates continued revenue growth as it expands its insurance payor base and increases scan volumes. Additionally, research and development expenses are expected to rise as the CLARITY Trial enrollment expands.SEC Filing: Aclarion, Inc. [ ACON ] - 10-Q - Nov. 12, 2025